WCA
CPRX

Westover Capital Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Westover Capital Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$263K Hold
10,619
– – 0.05% 209
2025
Q4 		$248K Hold
10,619
– – 0.05% 209
2025
Q3 		$209K Sell
10,619
-18,338
-63% -$377K 0.04% 214
2025
Q2 		$628K Buy
28,957
+16,674
+136% +$394K 0.13% 129
2025
Q1 		$298K Sell
12,283
-222
-2% -$5K 0.07% 194
2024
Q4 		$261K Sell
12,505
-270
-2% -$5.8K 0.06% 201
2024
Q3 		$254K Sell
12,775
-1,677
-12% -$31.1K 0.05% 215
2024
Q2 		$224K Sell
14,452
-18
-0.1% -$280 0.06% 195
2024
Q1 		$231K Sell
14,470
-70,106
-83% -$1.06M 0.07% 165
2023
Q4 		$1.42M Sell
84,576
-942
-1% -$12.9K 0.46% 54
2023
Q3 		$1,000K Sell
85,518
-17,379
-17% -$232K 0.36% 68
2023
Q2 		$1.38M Buy
+102,897
New +$1.48M 0.48% 52

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Westover Capital Advisors's CPRX Position: Q1 2026 in Review

Westover Capital Advisors held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 10,619 shares worth $263K. The position accounts for 0.05% of the portfolio, ranked #209.

Westover Capital Advisors first reported a position in CPRX in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.42M in Q4 2023. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Westover Capital Advisors held 10,619 shares of Catalyst Pharmaceutical worth $263K as of Q1 2026.
  • Westover Capital Advisors left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
  • Catalyst Pharmaceutical made up 0.05% of Westover Capital Advisors's portfolio in Q1 2026, its #209 holding.
  • Westover Capital Advisors first reported a position in Catalyst Pharmaceutical in Q2 2023 and has held it in 12 quarters since.
  • Westover Capital Advisors's Catalyst Pharmaceutical position peaked at $1.42M in Q4 2023.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Westover Capital Advisors's 13F filing for Q1 2026, filed 5 May 2026.